Artcles symptoms and conditions

Artie commented below. I am posting Artie's comment back in a place where every one will see because I know the importance of arming yourself with research. I have worked for a major pharmaceutical company in my lifetime. I know that we need research and we need proof. Without that, we will be ignored.

Reply 1 minute ago on Apr 02, 2008 by artie81, #6536
Do you honestly think the people on this forum know how to interpret scholarly journal artcles?

Posted at 6:44 PM on Apr 02, 2008 by concernedcitizen, #29028
A British study suggests that Singulair should be studied for possible psychiatric adverse drugs reactions in children. I don't have this access to this journal so I have to try to find it. I will get back to you on what it says specifically. BMC Clin Pharmacol. 2008 Mar 17;8(1):1 Links Individual case safety reports in children in commonly used drug groups - signal detection.Brunlof G, Tukukino C, Wallerstedt SM. ABSTRACT: BACKGROUND: Due to few paediatric drug safety studies, knowledge on risks of drug treatment in children is limited. The knowledge needs to be increased to make proper risk-benefit analyses possible when treating paediatric patients with drugs. The aim of the present study was to investigate drug groups commonly used in children concerning type and frequency of individual case safety reports in children. METHODS: Number and type of individual case safety reports in the 30 groups of drugs (5th level ATC-code) most sold (number of defined daily doses) in outpatient treatment to children (<5 years old and experiencing psychiatric adverse drug reactions. CONCLUSION: The number of individual case safety reports per million defined daily doses varies in different groups of drugs. A possible signal for montelukast and psychiatric adverse drug reactions was found, which should be further explored. PMID: 18366638 The key sentence is: A POSSIBLE SIGNAL FOR MONTELUKAST (SINGULAIR) AND PSYCHIATRIC ADVERSE DRUG REACTIONS WAS FOUND, WHICH SHOULD BE FURTHER EXPLORED.

A British study suggests that Singulair should be studied for possible psychiatric adverse drugs reactions in children. I don't have this access to this journal so I have to try to find it. I will get back to you on what it says specifically.

BMC Clin Pharmacol. 2008 Mar 17;8(1):1 Links
Individual case safety reports in children in commonly used drug groups - signal detection.Brunlof G, Tukukino C, Wallerstedt SM.
ABSTRACT: BACKGROUND: Due to few paediatric drug safety studies, knowledge on risks of drug treatment in children is limited. The knowledge needs to be increased to make proper risk-benefit analyses possible when treating paediatric patients with drugs. The aim of the present study was to investigate drug groups commonly used in children concerning type and frequency of individual case safety reports in children. METHODS: Number and type of individual case safety reports in the 30 groups of drugs (5th level ATC-code) most sold (number of defined daily doses) in outpatient treatment to children (<5 years old and experiencing psychiatric adverse drug reactions. CONCLUSION: The number of individual case safety reports per million defined daily doses varies in different groups of drugs. A possible signal for montelukast and psychiatric adverse drug reactions was found, which should be further explored.

PMID: 18366638

The key sentence is:

A POSSIBLE SIGNAL FOR MONTELUKAST (SINGULAIR) AND PSYCHIATRIC ADVERSE DRUG REACTIONS WAS FOUND, WHICH SHOULD BE FURTHER EXPLORED.